Krilogy Financial’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Krilogy Financial’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-300	Closed	-$3K	–	842
2017 Q2	$3K	Buy	+300	New	+$1.93K	﹤0.01%	646

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Krilogy Financial's SGMO Position: Q3 2017 in Review

Krilogy Financial sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2017, closing a stake of 300 shares — an estimated $3K sold.

Krilogy Financial first reported a position in SGMO in Q2 2017 and held it in 1 quarter. The position peaked at $3K in Q2 2017. 148 funds tracked by Wall St. Rank hold SGMO as of Q3 2017.

Krilogy Financial reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2017 after selling out during the quarter.
Krilogy Financial sold 300 SANGAMO THERAPEUTICS INC shares in Q3 2017, an estimated $3K.
Krilogy Financial first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and held it in 1 quarter.
Krilogy Financial's SANGAMO THERAPEUTICS INC position peaked at $3K in Q2 2017.
148 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2017.

Based on Krilogy Financial's 13F filing for Q3 2017, filed 15 Nov 2017.